A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Summary

The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.

Timeline

Start

2026-05-27

Primary completion

2029-05

Completion

2029-05

Drugs

Indications